Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME study of [14C] PF-04449913 in healthy male volunteers
NCT02110342Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glasdegib in acute myeloid leukemia (AML), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Extrapolated Infinite Time at 7 days, Maximum Observed Plasma Concentration at 7 days and 5 more. Started May 2014; status: completed.
02
Drugs
glasdegib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02110342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02110342.